However, an abbreviated holiday week in the US does provide some intrigue in the IPO market, including the launch of Jupiter Neurosciences, which will begin trading on the Nasdaq Composite on Tuesday.
More than three million units will be available at a price ranging from $5 and $7 eachAnd According to the IPO filing listed with the US Securities and Exchange Commission.
The Florida-based project is developing drugs to treat neuroinflammation, a common feature in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other neurodegenerative conditions, including those caused by traumatic brain injury.
This drug — JOTROL — is still in clinical trials, but the once-daily pill shows promise as a potential treatment for Alzheimer’s disease. The active ingredient is resveratrol, a natural polyphenol found in red grapes, which has shown some efficacy in fighting the progression of Alzheimer’s disease. The company said in a press release that JOTROL delivers an “effective therapeutic dose” without causing gastrointestinal or stomach issues.
JOTROL is the most advanced drug in Jupiter’s pipeline.
Buyer got a Patented in 2020And and then Rebranded in September of 2021 They made additions to her executive team Shortly thereafter.
A study published last week Show encouraging results, although FDA approval is still on the horizon.
Wider market potential
The global market for Alzheimer’s disease alone Could exceed 25 billion dollars (£18.3 billion) by 2027, at a robust compound annual growth rate of 17.5%. Alzheimer’s disease is the most common cause of dementia. In the United States, an estimated 5.7 million people have Alzheimer’s disease, a number that is expected to rise to 14 million by 2050.
It is the sixth cause of death in the United States, with a wide range of treatments in various stages of clinical trials, although there are few effective treatments other than those that treat symptoms. Slow progression is the primary focus of most drugs in development, as there is no known cure.
More broadly, the Neurodegenerative Disease Treatment Market Could be close to 63 billion dollars (£46.2 billion) by 2027, albeit at a more modest compound annual growth rate of 7.2%. In addition to the conditions listed above, amyotrophic lateral sclerosis (Lou Gehrig’s disease) and multiple sclerosis are among the most common and gruesome neurodegenerative diseases.
The prevalence of such disorders and the stress on mental health and organic health resources has prompted research and investment in treatments, despite relatively limited progress to date.
While the United States is expected to dominate the market on both the research and usage sides, increasingly favorable conditions in Europe and an exceeding CAGR in the Pacific are likely to contribute to development in those regions as well.
Read more: Falling US crops lead to higher orange juice prices in the future
Ready to get started?
The difference between trading assets and contracts for difference
The main difference between trading CFDs and trading assets, such as commodities and stocks, is that you do not own the underlying asset when you are trading a CFD.
You can still profit if the market moves in your favour, or incur a loss if it moves against you. However, with traditional trading, you enter into a contract to exchange legal ownership of individual shares or commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of your CFD trade in order to open a position. But with traditional trading, you can buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there are fees when buying shares, for example.
CFDs attract overnight costs of making trades (unless you use 1-1) leverage, making them more suitable for short-term trading opportunities. Stocks and commodities are usually bought and held for a longer period. You may also pay a commission or broker fees when buying and selling assets directly and you will need a place to store them safely.
Capital com is an executive only company. The material presented on this website is for informational purposes only and should not be construed as investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capitalcom or its agents. We do not make any representations or warranties as to the accuracy or completeness of the information on this page. If you rely on the information on this page, you do so entirely at your own risk.